R. Previs, Maureen E. Cooper, Kyle C. Strickland, Heidi Ko, Michelle F. Green, F. Koohestani, S. Hastings, Zachary D. Wallen, S. Pabla, Jeffrey M. Conroy, M. Nesline, Shengle Zhang, Durga Prasad Dash, Brian J. Caveney, Marcia Eisenberg, Eric A Severson, Shakti H. Ramkissoon
{"title":"Comprehensive Genomic Testing: Tissue Stewardship and Best Practices","authors":"R. Previs, Maureen E. Cooper, Kyle C. Strickland, Heidi Ko, Michelle F. Green, F. Koohestani, S. Hastings, Zachary D. Wallen, S. Pabla, Jeffrey M. Conroy, M. Nesline, Shengle Zhang, Durga Prasad Dash, Brian J. Caveney, Marcia Eisenberg, Eric A Severson, Shakti H. Ramkissoon","doi":"10.25270/jcp.2024.03.01","DOIUrl":null,"url":null,"abstract":"Biomarker-driven targeted therapies have shaped the oncology treatment landscape for patients with advanced solid tumors over the past decade. Comprehensive genomic profiling (CGP) has played a key role in precision medicine as it enables simultaneous identification of multiple biomarkers to guide cancer diagnosis, therapy selection, and prognostication. As a result, tissue stewardship for successful CGP testing is paramount. In addition, widespread adoption of less invasive sampling techniques leaves less diagnostic tissue for additional or future testing as smaller biopsies are acquired. To help oncology care practitioners overcome these challenges, this paper provides an overview of current genomic testing methodologies and offers guidelines on best practices for tissue stewardship and preanalytic practices for successful CGP testing and efficient turnaround times for laboratory tests.","PeriodicalId":507805,"journal":{"name":"Journal of Clinical Pathways","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pathways","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25270/jcp.2024.03.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Biomarker-driven targeted therapies have shaped the oncology treatment landscape for patients with advanced solid tumors over the past decade. Comprehensive genomic profiling (CGP) has played a key role in precision medicine as it enables simultaneous identification of multiple biomarkers to guide cancer diagnosis, therapy selection, and prognostication. As a result, tissue stewardship for successful CGP testing is paramount. In addition, widespread adoption of less invasive sampling techniques leaves less diagnostic tissue for additional or future testing as smaller biopsies are acquired. To help oncology care practitioners overcome these challenges, this paper provides an overview of current genomic testing methodologies and offers guidelines on best practices for tissue stewardship and preanalytic practices for successful CGP testing and efficient turnaround times for laboratory tests.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
